Literature DB >> 15755760

Expression and activation of STAT3 in chronic proliferative immune complex glomerulonephritis and the effect of fosinopril.

Wuxing Zhang1, Xiangmei Chen, Suozhu Shi, Ribao Wei, Jianzhong Wang, Nobuaki Yamanaka, Quan Hong.   

Abstract

BACKGROUND: Signal transducers and activators of transcription (STATs) are cytoplasmic proteins that are activated in response to stimulation from various cytokines. Among these, STAT3 is an important member that has been implicated in the inflammatory proliferation of cells. We hypothesized that STAT3 may be activated in kidneys of rats having modified chronic immune complex glomerulonephritis, and that angiotensin-converting enzyme (ACE) inhibition with fosinopril may prevent the activation of STAT3 and subsequent upregulation of tissue inhibitor of metalloproteinase-1 (TIMP-1), which are effects that may explain the therapeutic effects of fosinopril on nephritis.
METHODS: Fifty-one Wistar rats were randomly divided into three groups that included a control group, a model group and a fosinopril group. Bovine serum albumin (BSA) nephritis was induced by subcutaneous immunization and daily intraperitoneal (i.p.) administration of BSA. To accentuate the nephritis, we performed uni-nephrectomy and gave 100 microg of lipopolysaccharide (LPS) as an i.p. injection. Macrophage infiltration (ED-1) was assessed with immunohistochemistry. The expression and activation of STAT3 and the expression of TIMP-1, one of the STAT3 downstream genes, were observed in renal tissues of rats by means of immunohistochemistry, electrophoretic mobility shift assay (EMSA), western blot and northern blot. The relationships between STAT3 phosphorylation, 24 h urinary protein excretion and TIMP-1 expression were also analysed.
RESULTS: Northern blot showed that the mRNA expression of both STAT3 and TIMP-1 was significantly increased in kidneys from the model group, but significantly decreased in the fosinopril group (P<0.05). Western blot analysis revealed similar increases in the expression of STAT3, phospho-STAT3 (p-STAT3) and TIMP-1 in the model group. Analysis of immunohistochemistry showed that STAT3 and p-STAT3 were expressed in very few cells of normal rats, that expression was strong in model rats and that this increased expression was attenuated in the fosinopril group (P<0.05). The expression of p-STAT3 in glomeruli was positively correlated with 24 h proteinuria as well as with glomerular TIMP-1 expression. Double staining showed that some ED-1-positive cells also contained p-STAT3-positive staining.
CONCLUSIONS: The present study showed that STAT3 is expressed and activated in kidneys of rats with modified immune complex glomerulonephritis. These rats also had increased ED-1-positive cells, with some cells showing simultaneous expression of p-STAT3 and ED-1, which may contribute to glomerular inflammatory proliferation and extracellular matrix accumulation. Finally, fosinopril downregulated STAT3 activation and ED-1 influx, which are effects that may attenuate renal damage in this model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755760     DOI: 10.1093/ndt/gfh652

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  12 in total

1.  Stat1 Regulates Lupus-like Chronic Graft-versus-Host Disease Severity via Interactions with Stat3.

Authors:  Wen-Hai Shao; Ana M Gamero; Yuxuan Zhen; Monica J Lobue; Stephen O Priest; Hazem J Albandar; Philip L Cohen
Journal:  J Immunol       Date:  2015-09-21       Impact factor: 5.422

2.  Silencing of CXCL12 performs a protective effect on C5b-9-induced injury in podocytes.

Authors:  Wengang Sha; Lei Shen; Ling Zhou; Deyu Xu; Jing Yang; Guoyuan Lu
Journal:  Int Urol Nephrol       Date:  2018-03-05       Impact factor: 2.370

3.  The pathogenesis of diclofenac induced immunoallergic hepatitis in a canine model of liver injury.

Authors:  Saravanakumar Selvaraj; Jung-Hwa Oh; Reinhard Spanel; Florian Länger; Hyoung-Yun Han; Eun-Hee Lee; Seokjoo Yoon; Jürgen Borlak
Journal:  Oncotarget       Date:  2017-09-23

4.  Growth factor Midkine is involved in the pathogenesis of renal injury induced by protein overload containing endotoxin.

Authors:  Kiyonari Kato; Tomoki Kosugi; Waichi Sato; Hanayo Arata-Kawai; Takenori Ozaki; Naotake Tsuboi; Isao Ito; Hideo Tawada; Yukio Yuzawa; Seiichi Matsuo; Kenji Kadomatsu; Shoichi Maruyama
Journal:  Clin Exp Nephrol       Date:  2011-03-01       Impact factor: 2.801

5.  IL-18 induces profibrotic renal tubular cell injury via STAT3 activation.

Authors:  Futoshi Matsui; Audrey Rhee; Karen L Hile; Hongji Zhang; Kirstan K Meldrum
Journal:  Am J Physiol Renal Physiol       Date:  2013-07-31

Review 6.  The role of the Janus kinase family/signal transducer and activator of transcription signaling pathway in fibrotic renal disease.

Authors:  Futoshi Matsui; Kirstan K Meldrum
Journal:  J Surg Res       Date:  2012-07-17       Impact factor: 2.192

Review 7.  Midkine in nephrogenesis, hypertension and kidney diseases.

Authors:  Waichi Sato; Yuka Sato
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

8.  Reno-protective effect and mechanism study of Huang Lian Jie Du Decoction on lupus nephritis MRL/lpr mice.

Authors:  Xiaoli Nie; Rong Deng; Lei Xiang; Pingping Jiang; Qi Xue
Journal:  BMC Complement Altern Med       Date:  2016-11-09       Impact factor: 3.659

9.  Mechanism of action of Tripterygium wilfordii for treatment of idiopathic membranous nephropathy based on network pharmacology.

Authors:  Honghong Shi; Yanjuan Hou; Xiaole Su; Jun Qiao; Qian Wang; Xiaojiao Guo; Zhihong Gao; Lihua Wang
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

10.  Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum-induced glomerulonephritis.

Authors:  Yan Dai; Leyi Gu; Weijie Yuan; Qing Yu; Zhaohui Ni; Michael J Ross; Lewis Kaufman; Huabao Xiong; David J Salant; John C He; Peter Y Chuang
Journal:  Kidney Int       Date:  2013-07-10       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.